Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6198-6204

  Weng, Wen Hui ^a   Åhlén, Jan ^a   Åström, Kristina ^a   Lui, Weng Onn ^a   Larsson, Catharina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON PROTEIN; EZRIN;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 9Q; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CELL MEMBRANE; CHROMOSOMES, HUMAN, PAIR 9; CYTOPLASM; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEIC ACID HYBRIDIZATION; PHOSPHOPROTEINS; PROGNOSIS; SARCOMA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 24344464300     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0548     Document Type: Article

References (24)

1. Enzinger FM, Weiss SW. Soft tissue tumors. 5th ed. St. Louis (MO): Mosby; 2001.
2. Fletcher CDM, Rydholm A, Singer S, Sundaram M, Coindre JM. World Health Organization classification of tumors: pathology and genetics of tumors of soft tissue and bone. In: Fletcher CDM, Unni KK, Mertens F, editors. Soft tissue tumors: epidemiology clinical features, histopathological typing and grading. Lyon (France): IARC; 2002. p. 12-8.
3. Angervall L, Kindblom LG, Rydholm A, Stener B. The diagnosis and prognosis of soft tissue tumors. Semin Diagn Pathol1986;3:240-58.
4. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 1994;259:1-31.
5. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:791-6.
6. Rööser B. Prognosis in soft tissue sarcoma. Acta Orthop Scand Suppl 1987;225:1-54.
7. Levine EA. Prognostic factors in soft tissue sarcoma. Semin Surg Oncol 1999;17:23-32.
8. Khanna C, Wan X, Bose S, Cassaday R, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-6.
9. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004;10:175-81.
10. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin. Integrators at the cell cortex. Nat Rev Mol Cell Biol 2002;3:586-99.
11. Hunter KW, Ezrin, a key component in tumor metastasis. Trends Mol Med 2004;10:201-4.
12. Gautreau A, Poullet P, Louvard D, Arpin M, Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/ Akt pathway. Proc Natl Acad Sci U S A 1999;96: 7300-5.
13. Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003;46:165-86.
14. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O. Ezrin in primary cutaneous melanoma. Mod Pathol 2005;18:503-10.
15. Geiger KD, Stoldt P, Schlote W, Derouiche A. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 2000;157:1785-93.
16. Makitie T, Carpen O, Vaheri A, Kivela T. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci 2001;42:2442-9.
17. Moilanen J, Lassus H, Leminen A,Vaheri A, Butzow R, Carpen O. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 2003;90:273-81.
18. Ahlen J, Wejde J, Brosjo O, et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 2005;11:206-16.
19. Weng WH, Åhlén J, Lui WO, et al. Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis. Br J Cancer 2003;89:720-6.
20. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F. Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett 1999;147:31-8.
21. Ohtani K, Sakamoto H, Rutherford T, et al. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett 2002;179:79-86.
22. Pang ST, Fang X, Valdman A, et al. Expression of ezrin in prostatic intraepithelial neoplasia. Urology 2004;63:609-12.
23. Curto M, McClatchey AI, Ezrin. A metastatic detER-Minant? Cancer Cell 2004;5:113-4.
24. Koon N, Schneider-Stock R, Sarlomo-Rikala M, et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 2004;53: 235-40.